Cargando…
Metabolomic Analysis of Exosomes Derived from Lung Cancer Cell Line H460 Treated with SH003 and Docetaxel
Exosomes released from tumor cells treated with cancer-targeting drugs reflect altered metabolic processes within the cells. Therefore, metabolites in exosomes can be used as markers to predict the therapeutic response or identify therapeutic targets. In this study, metabolite changes in exosomes we...
Autores principales: | Choi, Yu-Jeong, Lee, Kangwook, Jeong, Miso, Shin, Yong Cheol, Ko, Seong-Gyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695006/ https://www.ncbi.nlm.nih.gov/pubmed/36355120 http://dx.doi.org/10.3390/metabo12111037 |
Ejemplares similares
-
Herbal Prescription SH003 Alleviates Docetaxel-Induced Neuropathic Pain in C57BL/6 Mice
por: Lee, Kangwook, et al.
Publicado: (2021) -
SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer
por: Choi, Yu-Jeong, et al.
Publicado: (2022) -
SH003 suppresses breast cancer growth by accumulating p62 in autolysosomes
por: Choi, Youn Kyung, et al.
Publicado: (2016) -
SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2
por: Choi, Hyeong Sim, et al.
Publicado: (2016) -
State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent
por: Lee, Kangwook, et al.
Publicado: (2022)